Aims & Scope

As an official publication of the International Society for Human and Animal Mycology (ISHAM), *Medical Mycology*, is an international journal, which focuses on original and innovative studies of all aspects of medical, veterinary and environmental mycology. The topics include, but are not limited to, mycological, biochemical and molecular investigations of etiological agents of mycoses; aspects of pathogenesis, immunology, and epidemiology of mycoses; laboratory approaches to the identification of fungal pathogens; antifungal susceptibility, therapy and prophylaxis; mode of antifungal action; pharmacokinetics and assessments of new antifungal agents; and investigations of the mycological aspects of the indoor environment, with a focus on human and animal health. The aim of the journal is to present the preeminent scientific reports on these aspects of mycology to provide a comprehensive reference base for medical mycologists, microbiologists, clinicians, and environmental specialists.

Types of Papers Considered for Publication

1. Types of Papers

1.1 Original Papers. Manuscripts must have: (a) a Cover-Page that includes the full title and a short title, name(s) and affiliation(s) of all author(s), the name, telephone/ fax numbers and email address of the designated corresponding author, and a list of up to five keywords; (b) a separate page for a Summary or Abstract of up to 250 words prepared without sub headers; (c) text consisting of Introduction, Materials and methods, Results, Discussion and References; (d) References must be numbered sequentially in the order in which they first appear in the text, the numbers cited in the text within non-superscript, square brackets, e.g., [1] and included in the same numerical order in the Reference section; (e) each Table should be submitted as a separate page and should have footnoted descriptions of all abbreviations contained in the Table (see section below on Tables for more detailed information); (f) each Figure should be submitted as a separate file (page), with appropriate figure legends allowing a reader to understand their contents without reference to the text (see section below on Figures for more detailed information). Manuscripts MUST be in English, double-spaced, in no less than size 12 point, without line numbering and up to approximately 30 manuscript pages (10-12 print pages) including cover-page, abstract, text, references, and tables/figures.

1.2 Reviews. Authors must first electronically submit an outline of their proposed article for evaluation by the journal. The outline should be no more than two, double-spaced pages in 12 point, in which the authors describe the objectives and contents of the report. The outline must be submitted to the Reviews Editor, Wiley Schell: wiley.schell@duke.edu. Once the proposal has been evaluated, the authors will be informed of the results of the Review Editor’s initial consideration of their proposal. Reviews are NOT restricted by the formatting or length requirements of Original Papers.

1.3 Case Reports. Such articles should be submitted to *Medical Mycology* Case Reports via www.ees.elsevier.com/mmcr from which all information pertaining to this on-line, open access ISHAM journal may be obtained.
1.4 Short Communications. These manuscripts are to provide an opportunity for the presentation of preliminary or brief observations that do not warrant an original paper. The manuscript should be prepared as an original paper, except they may be no more than 12–15 manuscript pages (approximately 5–7 print pages) including cover-page, abstract, text, references, and tables/figures.

1.5 Letters to the Editor. Letters are to allow readers the opportunity to discuss issues related to previously published original articles, short communications, and reviews in Medical Mycology. Letters are NOT to be used for the presentation of the authors’ preliminary data from their own investigations. Letters should be no more than 5 double-spaced manuscript pages including references (approximately 2 print pages), in no less than size 12 point.

2. Submission of Manuscripts

All submissions MUST be uploaded as Word files to the Medical Mycology ScholarOne site at mc.manuscriptcentral.com/tmmy. Users who have not previously submitted work through this site must create an account from the link on the login page. Assistance with this and all other areas of the site is available in the User Guide, which is accessed via the ‘Get Help Now’ button at the top right corner of all ScholarOne Manuscript web pages.

Manuscript Structure

1. Preparation of Manuscripts

Manuscripts MUST be in English, double-spaced, in no less than size 12 point, organized as appropriate for the manuscript type and have one inch margins all around. Statistics and measurements should be given in numerals when followed by a unit, e.g., mg, ml, etc. In contrast, numerals employed in other circumstance, e.g., two patients, should be spelled out if less than ten (10). ALL abbreviations, even those commonly used in medical mycology, e.g., Sabouraud glucose agar (SGA), must be defined when first used in the abstract and text. Please NOTE that the inability of authors to clearly present the contents of their submissions in English may constitute grounds for the immediate rejection of the papers or their return to authors so that they can correct their English usage prior to assignment to an associate editor.

For authors who require professional assistance with English usage, there are companies that will provide assistance for a fee. A list of these companies and contact information may be obtained from the Editor-in-Chief.

2. References

In preparing your citations please note that software programs available to format references MAY OR MAY NOT contain a format style option for Medical Mycology or for the use of the Vancouver system. Consequently, such programs should be used cautiously and should be carefully reviewed by the authors to ensure that citations meet the style/format requirements.

INSTRUCTIONS FOR AUTHORS-MARCH, 2012  Page 2
of the journal. References must be numbered sequentially in the order in which they first appear in the text, the numbers cited in the text within square brackets, i.e., [1], at the end of the sentences in which they appear, before the punctuation. They should be included in the same numerical order in the Reference section. **Citation numbers MUST NOT be indicated in superscript.** Articles with six or more authors are to be cited by the names of the first three authors, with the remaining authors replaced by *et al.* Journal names must be abbreviated, without the use of periods, in italic font. The volume number must be in **bold** font, issue numbers are not to be included and all page numbers must appear for each citation (e.g. 105-107, NOT 105-7).

### 2.1 Journal article
Author AB, Author CD, Author EF, *et al.* [if six or more] Title of paper. *J Title Abbrev* 1995; **00**: 000–000. If the title is in a language other than English, the authors should provide the English translation. The name of the original language should be included within a bracket, e.g., [in Spanish], after pagination at the end of the citation.

### 2.2 Book chapter
Author AB, Author CD, Author EF, *et al.* [if six or more] Chapter title. In: Editor AB, Editor CD, eds. *Book Title With Initial Uppercase Letters* (as indicated here and in italic font), 5th edn. Place: Publisher, 1995: 000–000.

### 2.3 Book
Author AB, Author CD (eds). *Book Title With Initial Uppercase Letters* (as indicated here and in italic font), 5th edn. Place: Publisher, 1995.

### 2.4 Thesis

### 2.5 Conference proceedings/Supplements

### 2.6 Meeting abstracts
Abstracts of works presented at scientific meetings should be cited in brackets within the text of the manuscripts rather than in the Reference sections. The citations should be formatted as: Author AB. Abstract title. Name of meeting, its location, the date and abstract number.

### 2.7 Personal communications, Unpublished results etc.
References to personal communications, unpublished results and papers submitted for publication (but not yet accepted) should only appear in brackets in the text, and in the following form: [A. B. Author, unpublished results] or [C. D. Author, personal communication].

### 2.8 Journal article on the Internet
Abood S. Quality improvement initiative in nursing homes: the ANA acts in an advisory role.
INSTRUCTIONS FOR AUTHORS


2.9 Monograph on the Internet

2.10 Homepage/Web site

2.11 Part of a homepage/Web site

2.12 Database on the Internet
Open database:

Closed database:

2.13 Part of a database on the Internet

3. Tables
Tables should present only essential data, must be numbered sequentially in the order in which they are first referenced in the text, and all MUST be referred to in the text. Each table should be supplied as a separate file (page) and not imbedded within the body of the text. The table header should be brief and self explanatory. If it contains generic and species names, these must be spelled out in full, e.g., Candida albicans, not C. albicans. Column headings should be brief and include units in parentheses where applicable. Only horizontal rule lines should be used and then only for headers and footers. Tables should be considered as ‘stand
alone’ documents through which data are summarized for presentation to readers. As such, all abbreviations employed in the tables MUST be defined by footnotes included directly below the tables.

4. Figures/Images

Images should be submitted as TIF, EPS, PDF or JPG (preferred) files. Scanned images should be of a sufficient resolution, i.e., 300 dpi for halftones/color, 500 dpi for combination halftones and 1000–1200 dpi for line art. Illustrations should be submitted as individual files, separate from the manuscript text file. The journal has a limited number of free color pages within its annual page allowance provided by the publisher. Therefore, authors may be required to pay USD 1150 for color reproduction in the print version of the journal. However, any figure submitted as a color original may appear in color in the journal's on-line edition, without any charges being assessed to the authors. NO part of any image may be enhanced, removed, relocated, introduced or manipulated in any manner after the capture of the original image unless the authors provide the editor with a clear and accurate description of the nature of the image manipulation.

Figures, like Tables, should be considered as ‘stand alone’ components of the manuscript. As such, authors should provide legends at the end of the text, following the Reference section, which clearly describe the significant features of the illustrated objects. In addition, authors may employ, as warranted, arrows or similar indicators in the figures to assist readers.

5. Supplementary Files

Supplementary information, including extensive data sets, large figures, audio and DVD/video material, can be made available as part of the on-line version of your manuscript. Please do not include supplementary information within the main manuscript file, but upload the material as separate file(s), labelled as ‘Supplemental Digital Content’. Please include a sequential number (S1, S2 etc) for each file and a brief description of the content at the appropriate position in the text and a list of the files at the end of the discussion. Please note that supplementary files are not copy-edited and will be presented as submitted.

6. Nomenclature

Proposals of new fungal taxa MUST conform to the requirements outlined in the International Code of Nomenclature for Algae, Fungi, and Plants. Some of the provisions are effective as of January 1, 2012, while others will subsequently become effective. The proposed taxon must be supported by deposition of cultures and/or the unique nucleotide and/or amino acid sequences in appropriate collections or databases, along with the new binomial. The identifier assigned to the taxon by these recognized repositories, e.g., Mycobank, must be included in the text, tables and figures. In addition, binomials should appear in italics, must be spelled out in full when first used in the abstract, text, figures/tables. Thereafter, a generic name may be abbreviated to the first initial only, e.g., Candida albicans when first cited and C. albicans in the remainder of the abstract and text, except at the
beginning of a sentence where the genus should be spelled out in entirety. Species names may NEVER be used without the generic full name or abbreviation combined with the full name of the species. For example, it must be *Candida albicans* or *C. albicans*, but never *albicans*, or *C. neoformans* var. *grubii* but never var. *grubii*. The use of abbreviations of generic and species names, e.g., (Ca) for *C. albicans*, in the text is NOT permitted.

7. Nucleotide and/or Amino Acid Sequence Data

Nucleotide and/or amino acid sequence data must be deposited in a freely accessible database. The GenBank/EMBL/DDBJ accession numbers should be included in the Materials and Methods Section of the manuscript. However, in a figure of a phylogenetic tree, the numbers should be shown along with species names (e.g., *Malassezia globosa* AB099880) (No descriptions are needed in the Materials and Methods Section in this case).

**Required Statements**

1. **Humans in Research**

When reporting investigations involving human subjects, authors must indicate in the manuscript if the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation within their institutions and/or with the Helsinki Declaration of 1975, as revised in 1983.

2. **Animals in Research**

Manuscripts containing information related to the experimental use of animals must clearly state that the studies complied with relevant professional and institutional animal welfare policies. Specifically, that procedures involving animals conformed to the ILAR Guide for the Care and Use of Laboratory Animals (2011 or later editions) of the Institute of Laboratory Animal Research, Commission on Life Sciences, National Research Council (www.nap.edu/catalog/5140.html).

3. **Authorship Contributions**

Please note that in submitting this manuscript you and your co-authors are confirming that all authors have, in accord with the Committee on Publication Ethics guidelines, (a) made a substantial contribution to the conception and design, acquisition of data, and/or analysis and interpretation of data, (b) participated in the drafting of the article or revising it critically for important intellectual content, (c) have read and approved the final manuscript, AND (d) that the manuscript is not, either in whole or in part, currently under consideration by any other scientific journal and has not been previously published in either hard copy or electronic format. Except for those submitting the manuscript, members of Study Groups should not be individually cited as authors.

Submissions with ten or more authors will ONLY be considered if the corresponding authors provide, in their cover letters, descriptions of each of the author’s contributions. Manuscripts drafted or written, in whole or part, by individuals other than those indicated as
authors will NOT be considered for publication unless the contributions of these individuals are clearly and accurately presented in the Acknowledgment section of the paper.

4. Acknowledgments

The work of other individuals who assisted in the studies or in the preparation of the submission must be specifically indicated in the Acknowledgment section of the paper.

5. Disclosures of Potential Conflicts of Interest

Although there is no standard definition of Conflict of Interest, the United States National Institutes of Health has published the following statement:

It is the sole responsibility of authors to disclose any affiliation with any organization with a financial interest, direct or indirect, in the subject matter or materials discussed in the manuscript (such as consultancies, employment, expert testimony, honoraria, speakers bureaus, retainers, stock options or ownership) that may be perceived as potentially affecting the conduct or reporting of the work submitted. All sources of funding are to be explicitly stated. If uncertain as to what might be considered a potential conflict of interest, authors should err on the side of full disclosure (i.e., when in doubt, provide full disclosure).

In addition, a conflict of interest may be perceived to exist in such situations as when authors are affiliated with or employed by a private enterprise whose product or competitor’s product, e.g., drug, device or diagnostic kit, is the focal point of the paper.

Information about potential conflict of interest must be clearly stated at the point of submission. This may be made available to reviewers and may be published with the manuscript at the discretion of the Editors and Publisher. The journal recommends that you and your co-authors include the sub header, ‘Conflict of Interest’, in the Acknowledgment section at the end of your manuscript. If no such conflict exists, simply respond ‘None’. If you or your co-authors have received funding that meets the criteria described in the paragraph above, the source(s) of the funds must be declared (NOTE – you are NOT required to disclose the amounts of funding that you or your co-authors have received). Furthermore, authors must indicate their employment if describing their or other companies’ products.

The intent of this policy is not to prevent authors with these relationships from publishing work, but rather to adopt transparency such that readers can make objective judgments on conclusions drawn.

Post Acceptance Information

1. Electronic Proofs
When proofs are ready, corresponding authors will receive e-mail notification with a password and Web address from which to download a PDF. Hard copies of proofs will NOT be mailed. To avoid delays in publication, corrections to proofs must be returned, within 48 hours of receipt.

2. Offprints

Corresponding authors will receive an email with information on how to, at no expense, download a PDF of the final published version of the paper. Additionally, authors are also able to order fifty complimentary offprints.

3. Copyright

It is a condition of publication that authors assign copyright or license the publication rights of their articles, including abstracts, to ISHAM. However, special provisions are made for government employees who are not allowed to assign copyright for work conducted as part of their official functions. The second page of the copyright release form clearly describes these provisions. In all other instances, the release of copyright to the society allows it to ensure full copyright protection and to disseminate the article, and the journal, to the widest possible readership in print and electronic formats as appropriate. Authors may, of course, use the article elsewhere after publication without prior permission from Informa UK Ltd., provided that acknowledgment is given to the journal as the original source of publication, and that Informa Healthcare is notified so that records show that its use was properly authorized. Authors retain a number of other rights under the Informa UK Ltd. rights policies documents.

4. NIH Public Access Policy

In consideration of the National Institutes of Health (NIH) and Wellcome Trust Public Access Policies, Informa Healthcare acknowledges that the broad and open dissemination of NIH/Wellcome-funded research benefits future scientific endeavour. Because we value the contribution our journals make to the body of scientific knowledge, our policies accommodate authors who wish to submit to PubMed Central/UK PubMed Central.

1. Informa Healthcare will deposit funded work to PubMed Central/UK PubMed Central for public access posting 12 months (NIH) or 6 months (Wellcome Trust) after final publication in electronic form.

2. ‘Funded work’ shall be defined as the final peer-reviewed manuscript, which was accepted for publication and that reflects any author-agreed changes made in response to the peer review.

3. This embargo period begins upon final publication of the article in print or electronic form (whichever is sooner).

File name = med myco/instructions for authors - Informa